drugset / Trial / NCT00685425

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

NCT00685425

Phase 3 Completed 62 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma

Timeline

Start
2002-10
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Levalbuterol Other / unclassified 45 ug
Subject Levalbuterol Other / unclassified 90 ug
Subject Levalbuterol Other / unclassified 180 ug
Comparator racemic albuterol Unknown 90 ug
Comparator racemic albuterol Unknown 180 ug
Comparator racemic albuterol Unknown 360 ug